Needham & Company LLC Reaffirms “Buy” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $3.00 price objective on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 167.86% from the stock’s current price.

LUCD has been the topic of several other research reports. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Lucid Diagnostics has a consensus rating of “Moderate Buy” and a consensus target price of $3.94.

Lucid Diagnostics Price Performance

LUCD opened at $1.12 on Thursday. The stock has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.18. The firm has a market cap of $154.20 million, a PE ratio of -1.17 and a beta of 1.18. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.39 million. As a group, sell-side analysts anticipate that Lucid Diagnostics will post -0.84 EPS for the current year.

Institutional Trading of Lucid Diagnostics

A number of institutional investors have recently made changes to their positions in LUCD. Bank of America Corp DE grew its stake in shares of Lucid Diagnostics by 41.5% in the third quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock worth $41,000 after acquiring an additional 11,917 shares during the period. Goldman Sachs Group Inc. lifted its position in Lucid Diagnostics by 35.7% during the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after purchasing an additional 22,727 shares during the period. Quadrature Capital Ltd bought a new position in Lucid Diagnostics during the second quarter valued at approximately $29,000. Centiva Capital LP purchased a new stake in Lucid Diagnostics in the third quarter worth approximately $25,000. Finally, Sprott Inc. bought a new stake in Lucid Diagnostics in the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

More Lucid Diagnostics News

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Won expanded access with the U.S. Department of Veterans Affairs and is pushing for Medicare/commercial payer wins, which could materially enlarge addressable market and reimbursement prospects. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume
• Positive Sentiment: Strong test-volume growth: management reported ~29% sequential growth in EsoGuard tests processed (3,664 tests in Q4), indicating improving commercial traction. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Revenue slightly beat consensus ($1.50M reported vs. $1.39M expected), showing top-line improvement versus prior-year quarter. Zacks: Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company highlighted strengthened clinical evidence with positive real‑world data (largest reported experience for esophageal precancer detection), which can support adoption and payer discussions. PR Newswire: Business Update & Financial Results
• Positive Sentiment: Analyst backing: Needham reaffirmed a “buy” rating with a $3.00 price target, representing sizable upside from current levels if execution continues. Benzinga: Needham Reaffirms Buy
• Neutral Sentiment: Company hosted a Q4 business update and provided slides/webcast; multiple earnings-call transcripts and slides are available for investors evaluating management commentary and forward guidance. Quarterly Press Release / Slide Deck
• Negative Sentiment: Earnings miss on profitability: Lucid reported a Q4 EPS of -$0.10 vs. consensus -$0.07, a larger-than-expected loss that likely drove near-term selling pressure despite revenue strength. InsiderMonkey: Q4 2025 Earnings Call Transcript

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.